IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科
学科主题临床医学
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Zhao, Shui-ping1; Yu, Bi-lian1; Peng, Dao-quan1; Huo, Yong2
关键词Acute coronary syndrome LDL cholesterol Lipid-lowering Statins
刊名ATHEROSCLEROSIS
2014-04-01
DOI10.1016/j.atherosclerosis.2013.12.003
233期:2页:707-712
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Peripheral Vascular Disease
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]DENSITY-LIPOPROTEIN CHOLESTEROL ; MYOCARDIAL-INFARCTION ; ATORVASTATIN ; MANAGEMENT ; THERAPY ; DISEASE ; EVENTS ; PRAVASTATIN ; PREVENTION ; GUIDELINES
英文摘要

Background: Current guidelines recommend intensive low-density lipoprotein (LDL) cholesterol lowering with statins, with a target of 70 mg/dL (1.81 mmol/L) LDL cholesterol for those with a very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid-lowering therapy with statins on acute coronary syndrome (ACS) in a Chinese population with low baseline LDL cholesterol levels.

Methods and results: Patients (n = 1355) with ACS were treated with a moderate dose of statin (atorvastatin 10 mg/d, or equivalent dose of other statins, n = 675) or with an intensive dose of statin (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins, n = 680) for 2 years. The primary end points were cardiac death, non-fatal acute myocardial infarction (MI), revascularization, ischemic stroke and documented unstable angina or severe heart failure requiring emergency hospitalization. Baseline lipid levels were nearly identical in both groups with a mean LDL cholesterol level of 2.7 mmol/L (103 mg/dL). At 3 months, LDL cholesterol levels declined 20.2% in the moderate dose statin group and 26.6% in the intensive statin group, respectively (P < 0.001). In a 2-year follow-up, a primary end point event occurred in 20 patients in the moderate dose statin group and in 28 patients in the intensive statin group. There was no significant between-group difference in the primary outcome (hazard ratio, 1.39; 95% confidence interval [CI], 0.78-2.46; P = 0.245).

Conclusions: For ACS patients with a relatively low baseline LDL cholesterol level who received optimized current medication and interventional therapy, the incremental LDL cholesterol reduction of 6.4% achieved by double-dose statin did not bring significant clinical effectiveness. (C) 2014 Published by Elsevier Ireland Ltd.

语种英语
WOS记录号WOS:000334337200060
资助机构"The 11th Five-Year Plan" of PR China
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62503
专题北京大学第一临床医学院_心血管内科
作者单位1.Cent S Univ, Xiangya Hosp 2, Dept Cardiol, Changsha, Hunan, Peoples R China
2.Peking Univ, Hosp 1, Dept Cardiol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Zhao, Shui-ping,Yu, Bi-lian,Peng, Dao-quan,et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial[J]. ATHEROSCLEROSIS,2014,233(2):707-712.
APA Zhao, Shui-ping,Yu, Bi-lian,Peng, Dao-quan,&Huo, Yong.(2014).The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.ATHEROSCLEROSIS,233(2),707-712.
MLA Zhao, Shui-ping,et al."The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial".ATHEROSCLEROSIS 233.2(2014):707-712.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhao, Shui-ping]的文章
[Yu, Bi-lian]的文章
[Peng, Dao-quan]的文章
百度学术
百度学术中相似的文章
[Zhao, Shui-ping]的文章
[Yu, Bi-lian]的文章
[Peng, Dao-quan]的文章
必应学术
必应学术中相似的文章
[Zhao, Shui-ping]的文章
[Yu, Bi-lian]的文章
[Peng, Dao-quan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。